Quick answer
Blend or separate vials? Choose the co-lyophilized blend when the design wants a fixed 1:1 mass ratio, one preparation step and one lot record. Choose separate CJC-1295 (no DAC) and ipamorelin vials when the design varies the ratio, tests each peptide alone, needs different storage histories, or measures interaction. Neither choice changes the chemistry of the peptides; it changes which questions the material can answer and how much preparation error enters. Volumes follow the formula concentration = mass ÷ volume, and the calculator does the arithmetic. Supplied for laboratory research use only.
The decision between one vial and two is often framed as convenience. In a laboratory it is a design decision, because the format fixes variables before the first measurement. This guide sorts the choice by experiment type and by practical logistics, and deliberately avoids repeating the supply-side comparison in blend versus separate vials or the chemistry in the blend explainer. For laboratory research use only; not for human consumption.
What the two formats physically are
The blend page lists a single co-lyophilized vial with CJC-1295 (no DAC) and ipamorelin at 1:1 by mass, in 5 mg / 5 mg and 10 mg / 10 mg sizes, ≥98% HPLC purity, stored at 2–8 °C with −20 °C for long-term. The separate route uses the CJC-1295 (No DAC) vial (5 mg or 10 mg) and the ipamorelin 10 mg vial, each a lyophilized powder in sealed clear glass.
| Feature | Co-lyophilized blend | Two single-peptide vials |
|---|---|---|
| Ratio of the two peptides | Fixed at 1:1 by mass | Chosen by the experimenter |
| Preparation steps | One reconstitution | Two reconstitutions plus mixing |
| Single-peptide arms | Not possible from the vial | Built in |
| Lot records | One lot for both | Two lots to track |
| Storage history | Shared by both peptides | Independent |
| Pipetting error sources | One dilution series | Two series; ratio error possible |
Decision by experiment type
Start from the claim the experiment will support. The right-hand column is a design argument, not a product recommendation.
| Experiment goal | Better format | Reason |
|---|---|---|
| Show that a combined GHRH-analog and secretagogue stimulus gives a response in a new cell model | Blend | Descriptive question; the fixed ratio is an acceptable constant |
| Compare combined response with each peptide alone | Separate | Needs single-peptide arms from matched stocks |
| Build a ratio response surface (several CJC : ipamorelin ratios) | Separate | A fixed vial cannot vary the ratio |
| Run many identical replicates of one combination over weeks | Blend | One lot and one preparation method reduce between-run variance |
| Test an antagonist selective for one receptor | Separate, or blend plus separate controls | Need to know which peptide carries the response |
| Stability study of each peptide in solution | Separate | Isolates each peptide’s own degradation from the other |
| Training or assay-development runs | Blend | Fewer variables while the method is being built |
The underlying logic is that an interaction can only be inferred by comparing the combination with its parts. Guidance on animal experiment design makes the general point that the comparison groups define what the study can conclude (Festing and Altman, 2002), and the same applies to well plates.
Why the ratio is not as simple as 1:1
The blend is 1:1 by mass, which is not 1:1 by molecules. CJC-1295 (no DAC) has a molar mass near 3,368 g/mol, and ipamorelin near 712 g/mol, from the formulas on the product pages. Dividing mass by molar mass gives moles, so a vial with equal masses contains roughly 4.7 times as many ipamorelin molecules as CJC-1295 molecules. If an experiment is specified in moles per liter, the two peptides in the blend are not at equal concentration.
Separate vials let a laboratory choose its convention. Pick equal moles, equal mass, or a ratio drawn from the potency data in the literature. Raun and colleagues (1998) reported ipamorelin potency in rat pituitary cells in nanomolar units, a convention that favors molar thinking. The conversion is simple: molar concentration = (mass concentration ÷ molar mass). Whatever is chosen has to be written in the methods section, because the two conventions give different outcomes.
Logistics that favor each format
Where the blend is easier. One reconstitution removes one source of arithmetic error. A single vial also means one lot number in the notebook and one appearance check on preparation. For a repeated-measures design over many weeks, a constant material is a benefit.
Where separate vials are easier. A project may use only one of the two peptides in some assays, and a combined vial would waste the other. Storage may differ: the CJC-1295 analog is a longer peptide with more sites for slow chemical change, while the pentapeptide is simple (see the chemistry discussion in the CJC-1295 No DAC overview and the ipamorelin overview). Separate stocks can be aliquoted and expired on their own schedules. If one peptide is later found to be degraded, a combined stock must be discarded entirely.
The reconstitution method is the same for both formats, and how to reconstitute a lyophilized peptide sets it out. Volumes are worked with the formula concentration = mass ÷ volume of diluent, or with the reconstitution volume calculations guide.
Mixing separate stocks without making errors
If two stocks are combined, error enters through the preparation. A few habits keep it small.
- Prepare each stock at a concentration that makes the working volumes comfortably pipettable, since very small volumes carry large relative error.
- Mix by volume from stocks of known molarity, then calculate the working concentration of each peptide using c₁V₁ = c₂V₂.
- Use fresh low-binding tips and tubes for each peptide to avoid carry-over, and record which stock went where.
- Prepare the combination immediately before use, because a mixed working solution has two stability clocks and no shared published shelf life.
- Prepare a mock mixture without peptide to show the vehicle by itself does not affect the readout.
The sum of the stock volumes also dilutes the buffer, so compare vehicles fairly. These steps reproduce, with more work, what the co-lyophilized vial provides in a single step, which is why the blend stays attractive for fixed-ratio work.
Quality documentation under each format
Both formats list a purity specification of ≥98% by HPLC, and sequence identity is reported on the certificate of analysis where one is published in the COA library. What changes is how many documents sit behind a result. A blend experiment cites one lot; a separate-stock experiment cites two, and the notebook should say so. The meaning of the fields on a certificate is covered in how to read a COA and the analytical approach in understanding HPLC purity. A purity percentage describes the main peak in a chromatogram and not the exact peptide content by weight, so a precise molar concentration claim needs a separate content determination if the study depends on it.
A short decision procedure
- Write the central claim as a sentence. If it contains the words “alone”, “interaction”, “ratio” or “which receptor”, use separate vials.
- If the claim is descriptive and the ratio is incidental, use the blend.
- If both are needed, use the blend for the main arm and separate vials for the control arms; the lots are then documented separately.
- Decide mass versus molar matching and write it down before the first dilution.
- Record vial size, lot, diluent, preparation time and storage for each stock.
For the background on pairing logic, see CJC-1295 and ipamorelin research overview and CJC-1295 versus ipamorelin.
Frequently asked questions
Is the CJC-1295 ipamorelin blend better than separate vials?
Neither is better in general. The blend suits fixed-ratio, repeated work with one preparation step. Separate vials suit single-peptide arms, variable ratios and independent storage. The experiment’s question decides.
Can a blend vial be used to vary the ratio of the two peptides?
No. The ratio is fixed at 1:1 by mass inside the vial. Varying it needs two separate stocks combined in chosen proportions.
Is the blend 1:1 by mass or by moles?
By mass. Because CJC-1295 is much larger than ipamorelin, the blend contains several times more ipamorelin molecules than CJC-1295 molecules.
How do I convert mass concentration to molar concentration?
Divide the mass concentration by the molar mass of the peptide. For example, mg/mL divided by g/mol gives mol/L when units are handled consistently.
Do separate vials add error?
They can, through two preparations and a mixing step. Using well-sized working volumes, fresh tips and a recorded mixing scheme keeps the error small.
Which format is better for a stability study?
Separate vials, because each peptide’s degradation can be followed without the influence of the other, and each stock can be aged independently.
How many lot numbers should be recorded?
One for a blend and two for separate vials. Include the COA reference where a certificate is published for the lot.
Can the blend be used as the main arm with separate controls?
Yes. That is a common compromise: the blend gives the combined condition and separate vials provide the single-peptide arms.
Do both formats have the same purity specification?
The product pages list ≥98% by HPLC for the blend and for each single peptide. Check the batch documentation where it is published.
Where does the reconstitution arithmetic come from?
Concentration equals mass divided by diluent volume. The reconstitution calculator on the site applies it to any vial size.
Related reading: CJC-1295 + Ipamorelin: Testing Additivity and Synergy, CJC-1295 + Ipamorelin Research Stack: Evidence Map, CJC-1295 Ipamorelin Blend: Lab Planning Guide.
References
- Festing MFW, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002;43(4):244-258. doi:10.1093/ilar.43.4.244
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
